$CMMB

Chemomab Therapeutics (CMMB) and Scipher Medicine agreed to merge, forming a Nasdaq-listed company trading as SCIP. The combined firm will advance nebokitug, an anti-CCL24 antibody, into a Phase 2 rheumatoid arthritis trial. Chemomab holders expected to own ~32% and Scipher ~68%, with contingent value rights. About $30M new funding; cash expected to fund through H2 2028. Deal expected to close Q4 2026; CMMB down to $2.39 pre-market.

Chemomab Therapeutics (Nasdaq: CMMB) and Scipher Medicine (Nasdaq-bound) announced a definitive merger in a stock deal, with the combined company to trade on Nasdaq as Scipher Medicine Corporation under ticker “SCIP”. The focus will be advancing nebokitug, an anti-CCL24 antibody, into a Phase 2 RA trial, with topline results expected in H1 2028. A $30M private placement is planned, valuing the deal at $150M pre-placement, and cash is expected to fund operations into H2 2028.

Chemomab Therapeutics (Nasdaq: CMMB) and Scipher Medicine (Nasdaq-bound) announced a definitive merger to combine in a stock deal, with the combined company to trade on Nasdaq as Scipher Medicine Corporation under ticker SCIP. The focus is advancing nebokitug, an anti-CCL24 antibody, into a Phase 2 RA trial using Scipher’s PrismRA test. A $30M private placement supports operations into H2 2028; Phase 2 readout expected H1 2028. Valuation cited at $150M pre-merger.

Biotech gainers included SL Science (SLBT), up 34.61% to $5.99 after Nasdaq trading began June 15; Chemomab (CMMB), up 33.53% to $2.27 as Phase 3 preparations for Nebokitug in primary sclerosing cholangitis continue; Propanc (PPCB), up 22.92% to $1.77 after a $500k buyback authorization. Also: VERAXA (VRXA) +18.26% to $2.04 with ATUM support; Tectonic (TECX) +15.85% to $37.93 ahead of Phase 2/1 catalysts; Aura (AURA) +15.01% to $7.74 ahead of bel-sar data; SELLAS (SLS) +12.89% to $14.98 with REG

Mor George Adi (Chief Executive Officer) purchased 4,926 shares of Chemomab Therapeutics Ltd. (CMMB) at $2.08 on 2026-05-29.

Mor George Adi (Chief Executive Officer) purchased 4,878 shares of Chemomab Therapeutics Ltd. (CMMB) at $2.05 on 2026-05-29.

Chemomab Therapeutics Ltd. has announced its Annual General Meeting for April 28, 2026, where shareholders will vote on four key proposals. These proposals include the re-election of two Class II directors, the approval of a refreshed compensation policy, a significant increase in authorized share capital by 8 billion ordinary shares, and the re-appointment of KPMG International's Somekh Chaikin as independent auditors for 2026. The increase in authorized share capital aims to provide the company with flexibility for future financing, strategic transactions, and equity compensation needs.

This page provides news and market updates for Chemomab Therapeutics Ltd. (CMMB), a clinical-stage biotechnology company developing nebokitug for fibro-inflammatory diseases, particularly primary sclerosing cholangitis (PSC). It highlights the company's clinical trial results, regulatory milestones, financial updates, and investor outreach activities. Recent news focuses on positive Phase 2 SPRING trial data for nebokitug in PSC and progress towards Phase 3 trials and regulatory approval.

TEL AVIV, Israel, Nov. 24, 2025 ( GLOBE NEWSWIRE ) -- Chemomab Therapeutics Ltd. ( NASDAQ:CMMB ) ( Chemomab ) , a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that co-founder and CEO Adi Mor, PhD, ...

PARR, CMMB and GES made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Oct. 23, 2025.